ALNOV.PA WACC - Weighted Average Cost of Capital
The WACC of Novacyt SA (ALNOV.PA) is 6.2%.
| Range | Selected | |
| Cost of equity | 5.7% - 7.6% | 6.65% |
| Tax rate | 4.4% - 8.0% | 6.2% |
| Cost of debt | 5.0% - 5.0% | 5% |
| WACC | 5.5% - 6.8% | 6.2% |
| Category | Low | High |
| Long-term bond rate | 3.0% | 3.5% |
| Equity market risk premium | 5.8% | 6.8% |
| Adjusted beta | 0.47 | 0.53 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.7% | 7.6% |
| Tax rate | 4.4% | 8.0% |
| Debt/Equity ratio | 0.35 | 0.35 |
| Cost of debt | 5.0% | 5.0% |
| After-tax WACC | 5.5% | 6.8% |
| Selected WACC | 6.2% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| ALNOV.PA | Novacyt SA | 0.35 | 1.39 | 1.04 |
| ALERS.PA | Eurobio Scientific SA | 0.13 | -0.71 | -0.63 |
| AZT.OL | Arcticzymes Technologies ASA | 0.01 | 0.62 | 0.62 |
| B8F.DE | Biofrontera AG | 1.3 | 0.33 | 0.15 |
| BIO.WA | Bioton SA | 0.16 | 0.23 | 0.2 |
| BONEX.ST | Bonesupport Holding AB | 0 | 0.18 | 0.18 |
| DBV.PA | DBV Technologies SA | 0.02 | 0.26 | 0.25 |
| HBC.OL | Hofseth Biocare ASA | 0.23 | 0.67 | 0.55 |
| ONCO.ST | Oncopeptides AB | 0.46 | -0.4 | -0.28 |
| PROB.ST | Probi AB | 0.15 | 0.1 | 0.09 |
| Low | High | |
| Unlevered beta | 0.17 | 0.22 |
| Relevered beta | 0.21 | 0.3 |
| Adjusted relevered beta | 0.47 | 0.53 |
ALNOV.PA's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for ALNOV.PA:
cost_of_equity (6.65%) = risk_free_rate (3.25%) + equity_risk_premium (6.30%) * adjusted_beta (0.47) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.